Información del artículo
Resumen
Siguiendo la tendencia de los últimos 2-3 años, los avances recientes más relevantes en el área de las lesiones GI asociadas a antiinflamatorios no esteroideos (AINE) se han centrado en los efectos secundarios en el intestino distal, más allá del duodeno, y en aspectos relacionados con la toxicidad asociada al tratamiento con antiplaquetarios (AP). Nuevos datos refuerzan que AINE y AP se asocian a incremento del riesgo de complicaciones graves, tanto en el tracto gastrointestinal superior como inferior, abriéndose varias líneas de investigación en prevención y terapia basadas en probióticos, antibióticos y agentes mucoprotectores. La interacción entre la infección por Helicobacter pylori, AINE y ácido acetilsalicílico sigue generando controversia, pero la interacción positiva con AINE parece reforzarse. Varias revisiones sistemáticas confirman que la combinación de varios fármacos gastrotóxicos potencia de manera notable el riesgo de hemorragia gastrointestinal, lo cual debe reforzar las actuales consideraciones en gastroprotección, y que los nuevos agentes anticoagulantes no parecen reducir el riesgo de hemorragia digestiva. Una vez que la hemorragia gastrointestinal se ha producido, varios estudios han señalado la necesidad de implementar escalas pronósticas más sencillas que las actuales. En el campo de la innovación destaca el diseño de un endoscopio desechable para estos casos y un nuevo material hemostático prometedor que se aplica localmente sobre la lesión sangrante.
Palabras clave:
Antiinflamatorios no esteroideos
Ácido acetilsalicílico
Clopidogrel
Anticoagulantes
Hemorragia gastrointestinal
Abstract
Following the trends observed for the last 2–3 years, the most significant and recent advances in the area of gastrointestinal lesions associated with anti-inflammatory drugs (NSAIDs) have focused on adverse effects in the distal intestine and on issues related to the toxicity associated with antiplatelet therapy. New data reinforce evidence that NSAIDs and antiplatelet therapy are associated with an increased risk of serious complications in both the upper and lower gastrointestinal tract, opening up several lines of research in prevention and therapy based on probiotics, antibiotics and mucosal protectants. The interaction between Helicobacter pylori infection and NSAIDs or aspirin remains controversial but a positive interaction between this bacterium and NSAIDs seems to be reinforced. Several systematic reviews confirm that the combination of gastrotoxic drugs significantly increases the risk of gastrointestinal bleeding, which should reinforce existing prevention strategies, and that new anticoagulant agents do not appear to reduce the risk of gastrointestinal bleeding. Once gastrointestinal hemorrhage has occurred, several studies have indicated the need to implement simpler prognostic scales than those used today. Notable innovations are the development of a disposable endoscope for acute upper gastrointestinal bleeding events and a promising new hemostatic technique, hemospray, applied locally over the bleeding lesion.
Keywords:
Non-steroidal antiinflammatory drugs
Aspirin
Clopidogrel
Anticoagulants
Gastrointestinal bleeding
El Texto completo está disponible en PDF
Bibliografía
[1.]
G.I. Leontiadis, Y. Yuan, F. Tse, R.H. Hunt, P. Moayyedi.
Risk of serious upper gastrointestinal (UGI) complications with concomitant use of non-selective NSAIDs and low-dose aspirin: A series of systematic reviews of randomized controlled trials (RCT), cohort studies and case control studies.
Gastroenterology, 142 (2012), pp. S1614
[2.]
G.I. Leontiadis, Y. Yuan, F. Tse, R.H. Hunt, P. Moayyedi.
Risk of serious upper gastrointestinal (UGI) complications in patients receiving multiple non-selective NSAIDs for at least 4 weeks: A series of systematic reviews and meta-analyses of randomized controlled trials (RCT), cohort and case control studies.
Gastroenterology, 142 (2012), pp. S1776
[3.]
G.I. Leontiadis, Y. Yuan, F. Tse, R.H. Hunt, P. Moayyedi.
Risk of serious upper gastrointestinal (UGI) complications with concomitant use of non-selective NSAIDs and clopidogrel for at least 4 weeks: A series of systematic reviews of randomized controlled trials (RCT), cohort studies and case control studies.
Gastroenterology, 142 (2012), pp. S1607
[4.]
G.I. Leontiadis, Y. Yuan, F. Tse, R.H. Hunt, P. Moayyedi.
Risk of serious upper gastrointestinal (UGI) complications with concomitant non-selective NSAID and anticoagulation therapy for at least 4 weeks: A series of systematic reviews of randomized controlled trials (RCT), cohort studies and case control studies.
Gastroenterology, 142 (2012), pp. S1771
[5.]
G.I. Leontiadis, Y. Yuan, F. Tse, R.H. Hunt, P. Moayyedi.
Risk of serious upper gastrointestinal (UGI) complications with use of nonselective (NS) NSAIDs for at least 4 weeks among patients with a history of peptic ulcer (PU) or PU complications: A series of systematic reviews and meta-analyses.
Gastroenterology, 142 (2012), pp. S1777
[6.]
G.I. Leontiadis, Y. Yuan, F. Tse, R.H. Hunt, P. Moayyedi.
Risk of serious upper gastrointestinal (UGI) complications in patients receiving non-selective NSAIDs for at least 4 weeks: A series of systematic reviews of randomized controlled trials (RCT), cohort studies and case control studies.
Gastroenterology, 142 (2012), pp. S1078
[7.]
R. Bahuva, A. Gupta s Atreja.
Increased risk of gastrointestinal (GI) bleeding with selective serotonin reuptake inhibitors (SSRI), used alone and with NSAIDs: Meta-analysis of case-control studies.
Gastroenterology, 142 (2012), pp. S1805
[8.]
N.L. De Groot, M.P. Hagenaars, H. Verkooijen, P. Siersema, M. Van Oijen.
Risk factors for upper gastrointestinal bleeding in short and long term NSAID users.
Gastroenterology, 142 (2012), pp. 482
[9.]
C.O. Musumba, D. Van Eker, A.L. Jorgensen, E. Zhang, N. O’Hara, M. Pritchard, et al.
CYP2C19*17 gain of function mutation is associated with the development of peptic ulcer disease.
Gastroenterology, 142 (2012), pp. 1780
[10.]
M.M. Tielemans, L.G. Van Rossum, J.J. Focks, R. Laheij, J.B. Jansen, M.G. Van Oijen.
Gastrointestinal symptoms are increased in both prescribed and over-the-counter NSAID users compared to non users in the community.
Gastroenterology, 142 (2012), pp. S485
[11.]
N.L. De Groot, M.P. Hagenaars, H.M. Verkooijen, P.D. Siersema, M.J. Van Oijen.
Time to upper gastrointestinal bleeding in NSAID and low-dose aspirin users: Results of a prospective cohort study.
Gastroenterology, 142 (2012), pp. S1789
[12.]
H.T. Hatoum, S.J. Lin, J.G. Fort, I. Witherell.
The likelihood of occurrence of serious gastrointestinal events associated with hospitalizations or emergency room visits after initiation of antiplatelet use for secondary cardiovascular prevention.
Gastroenterology, 142 (2012), pp. S115
[13.]
O. Kailani, M. Bokhoven, S. Mann.
Do patients with cardiovascular protection get adequate gastroprotection?.
Gastroenterology, 142 (2012), pp. S1779
[14.]
H.A. Daya, M.A. Eloubeidi, A.H. Malli, H. Halawi, Y. Dirani, H. Tamim, et al.
Gross non-variceal upper gastrointestinal bleeding in patients with peptic disease in the setting of antiplatelet and/or anticoagulant therapy: A study of clinical outcomes.
Gastroenterology, 142 (2012), pp. S1791
[15.]
T. Fujita, T. Sanuki, M. Murakami, Y. Matsubara, H. Kutsumi, T. Hayakumo, et al.
Efficacy of rabeprazole for preventing low-dose aspirin-induced gastroduodenal ulcers.
Gastroenterology, 142 (2012), pp. S1774
[16.]
T. Uotani, M. Sugimoto, M. Nishino, C. Kodaira, M. Yamade, S. Sahara, et al.
Role of clopidogrel and rabeprazole in low-dose aspirin- induced gastric mucosal injury in relation to CYP2C19 genotype.
Gastroenterology, 142 (2012), pp. S1064
[17.]
R. Casado-Arroyo, J.M. Scheiman, M. Polo-Tomas, S.D. Saini, A. Del Río, E. Guastello, et al.
Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States.
Aliment Pharmacol Ther, 32 (2010), pp. 689-695
[18.]
P. Henry, F. DePalma, P. Elbaum, N. Enyinna, M.E.l. Jarbrink-Sehga, L. Chaptini.
Adherence to gastroprotective agents in patients discharged on aspirin.
Gastroenterology, 142 (2012), pp. S1778
[19.]
S.C. Ng, R.S. Tang, H. Chan, J. Ching, Y. Tse, D. Chan, et al.
Clinical outcome of patients with non-variceal upper gastrointestinal bleeding on anti-thrombotics: A cohort of 2,096 patients.
Gastroenterology, 142 (2012), pp. S1799
[20.]
I.L. Holster, V.E. Valkhoff, E.J. Kuipers, E.T. Tjwa.
New oral anticoagulants and the risk of gastrointestinal bleeding: A systematic review.
Gastroenterology, 142 (2012), pp. S1788
[21.]
A. Lanas, L.A. García Rodríguez, P. Carrera, M.T. Arroyo, C. Sostres, P. Roncales, et al.
Helicobacter pylori infection and the risk of upper GI bleeding in patients taking NSAIDs or aspirin.
Gastroenterology, 142 (2012), pp. S486
[22.]
K. Iijima, N. Ara, Y. Abe, T. Koike, T. Iwabuchi, K. Uno, et al.
Paradoxical effects of H. pylori infection on low-dose aspirin induced gastropathy depending on the gastric acid secretion level.
Gastroenterology, 142 (2012), pp. S484
[23.]
C.H. Ho, Y. Tse, J. Ching, C. Kee, P.K. Cheong, A. Chan, et al.
Potentially reversible risk factors for peptic ulcer bleeding in averagerisk users of nonsteroidal anti-nflammatory drugs (NSAIDs) and low-dose aspirin (ASA).
Gastroenterology, 142 (2012), pp. S1772
[24.]
A. Lanas, L. Bujanda, C. Sostres, A. Pérez-Aisa, J. Ponce, M. Castro-Fernández, et al.
Risk of upper and lower GI bleeding in patients treated with NSAIDs ASA, clopidogrel or anticoagulants.
Gastroenterology, 142 (2012), pp. S854
[25.]
N. Abraham, A.D. Naik, P. Richardson, C.M. Hartman.
Complex antithrombotic therapy (CAT) and national risk of upper gastrointestinal bleeding (UGIB), lower gastrointestinal bleeding (LGIB), transfusions and hospitalizations.
Gastroenterology, 142 (2012), pp. S118
[26.]
F.K.L. Chan, E.L. Ki, Y. Tse, K.W.M. Au, J. Ching, G. Wong, et al.
Risk of recurrent lower gastrointestinal bleeding with continued lowdose aspirin therapy; a 10-year retrospective cohort study.
Gastroenterology, 142 (2012), pp. S483
[27.]
A. Watanabe, T. Tanigawa, Y. Nadatani, Y. Nagami, S. Sugimori, H. Okazaki, et al.
Prevalence and risk factors of severe nonsteroidal anti-inflammatory drug-induced small intestinal damage in patients with rheumatoid arthritis.
Gastroenterology, 142 (2012), pp. S1337
[28.]
F.K. Chan, A. Lanas, J. Scheiman, M.F. Berger, H. Nguyen, J.L. Goldstein.
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Lancet, 376 (2010), pp. 173-179
[29.]
J.L. Goldstein, X. Luo, J.L. Cappelleri, G. Sands.
Healthcare resource utilization and economic impact of a e2g/Dl decrease in hemoglobin after NSAID treatment in osteoarthritis patients.
Gastroenterology, 142 (2012), pp. S481
[30.]
S.D. Syer, W. McKnight, A. Aucouturier, R. Martin, P. Langella, J.L. Wallace.
Bifidobacteria exert a protective effect against NSAID-induced enteropathy that is dependent on lactate production.
Gastroenterology, 142 (2012), pp. S1724
[31.]
M.M. Zwolinska-Wcislo, P.C. Konturek, D. Drozdowicz, E. Karczewska, S. Kwiecien, K. Urbanczyk, et al.
Beneficial effects of probiotic Saccharomyces boulardi and rifaximine in stress- and NSAID-induced exacerbation of experimental colitis.
Gastroenterology, 142 (2012), pp. S186
[32.]
H. Endo, T. Higurashi, E. Sakai, K. Hosono, H. Ohkubo, E. Yamada, et al.
Efficacy of probiotic treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled trial.
Gastroenterology, 142 (2012), pp. S1066
[33.]
S. Kurokawa, S. Katsuki, M. Kato, T. Fujita, H. Ohta, Y. Saitoh, et al.
Healing effect of rebamipide in patients with chemical-induced small bowel complications –randomized, double-blinded, placebo-controlled, multicenter trial.
Gastroenterology, 142 (2012), pp. S1336
[34.]
T. Kuramoto, E. Umegaki, S. Nouda, K. Narabayashi, T. Inoue, M. Takii, et al.
Small intestinal mucosal adaptation in the long-term administration of a NSAID and the efficacy of irsogladine maleate, a gastroprptective drug, and omeprazole in healthy volunteers: A prospective randomized trial.
Gastroenterology, 142 (2012), pp. S1729
[35.]
A.N. Barkun, M. Bardou, E.J. Kuipers, J. Sung, R.H. Hunt, M. Martel, et al.
International Consensus Upper Gastrointestinal Bleeding Conference Group International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding.
Ann Intern Med, 152 (2010), pp. 101-113
[36.]
N.Q. Nguyen, R.V. Bryant, P. Kuo, K.D. Williamson, M. Schoeman, R.H. Holloway.
Risk stratification with Glasgow-Blatchford bleeding score for hospitalized patients with upper gastrointestinal bleeding can avoid the needs for urgent endo-therapy.
Gastroenterology, 142 (2012), pp. S1310
[37.]
D.W. Cheng, L.Y. Lu, T. Teller, H.K. Sekhon, B.U. Wu.
Use of a modified Glasgow Blatchford score improves risk stratification in upper gastrointestinal bleeding: prospective comparison against the Glasgow Blatchford, pre- endoscopy Rockall and full Rockall score.
Gastroenterology, 142 (2012), pp. S1082
[38.]
N. Khandelwal, G.S. Cooper, R.S. Wong.
Admission hematocrit is an independent risk factor for mortality, surgery, and length of stay in those with upper and lower acute gastrointestinal hemorrhage (GIH).
Gastroenterology, 142 (2012), pp. S1009
[39.]
V. Jairath, B.C. Kahan, S.J. Stanworth, S. Hearnshaw, R.F. Logan, S. Travis, et al.
Prevalence, management and outcomes of patients with coagulopathy following acute non-variceal upper gastrointestinal bleeding.
Gastroenterology, 142 (2012), pp. S1802
[40.]
J. Park, T.O. Kim, E.H. Seo, N.Y. Heo, S. Park, M. Young Soo.
Diagnostic usefulness of portable disposable endoscopy (E.G Scantm) for acute upper gastrointestinal bleeding: A feasibility study.
Gastroenterology, 142 (2012), pp. S1655
[41.]
L.A. Smith, A. Stanley, J.J. Bergman, R. Kiesslich, A. Hoffman, E.T. Tjwa, et al.
Hemospray for non-variceal upper gastrointestinal bleeding: Results of the Seal Dataset (Survey to Evaluate the Application of Hemospray in the Luminal Tract).
Gastroenterology, 142 (2012), pp. S284
[42.]
D. Ang, E.K. Teo, A. Tan, S. Ibrahim, T.L. Ang, K. Fock.
A comparison of surgery vs. transcatheter angiographic embolization in the treatment of non-variceal upper gastrointestinal bleeding uncontrolled by endoscopy.
Gastroenterology, 142 (2012), pp. S1787
[43.]
J.J. Sung, J.Y. Lau, J.Y. Ching, J.C. Wu, Y.T. Lee, P.W. Chiu, et al.
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
Ann Intern Med, 152 (2010), pp. 1-9
[44.]
N.L. De Groot, B.M. Spiegel, S.S. Karsan, C. Nordstrom, B.L. Snyder, P.D. Siersema, et al.
Adverse cardiovascular outcome after gastrointestinal bleeding; incidence and risk factors.
Gastroenterology, 142 (2012), pp. S1790
Copyright © 2012. Elsevier España, S.L.. Todos los derechos reservados
